Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
S63845
i
Other names:
S63845, NSC-798846, NSC798846, S-63845, NSC 798846, S 63845
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(17)
News
Trials
Company:
HitGen, Novartis, Servier
Drug class:
MCL1 inhibitor
Related drugs:
‹
AZD5991 (5)
omacetaxine mepesuccinate (4)
AMG 176 (3)
PRT1419 (2)
APG-3526 (1)
AT 101 (1)
ABBV-467 (0)
GS-9716 (0)
MIK665 (0)
Mcl-1 inhibitors (0)
TTX-810 (0)
TW-37 (0)
BS-HH-002.SA (0)
AMG 397 (0)
ONT-701 (0)
CYC202 (0)
AZD5991 (5)
omacetaxine mepesuccinate (4)
AMG 176 (3)
PRT1419 (2)
APG-3526 (1)
AT 101 (1)
ABBV-467 (0)
GS-9716 (0)
MIK665 (0)
Mcl-1 inhibitors (0)
TTX-810 (0)
TW-37 (0)
BS-HH-002.SA (0)
AMG 397 (0)
ONT-701 (0)
CYC202 (0)
›
Associations
(17)
News
Trials
VERI cancer hierarchy
Reset Filters
SS18-SSX fusion
Soft Tissue Sarcoma
SS18-SSX fusion
Soft Tissue Sarcoma
venetoclax + S63845
Sensitive: C3 – Early Trials
venetoclax + S63845
Sensitive
:
C3
venetoclax + S63845
Sensitive: C3 – Early Trials
venetoclax + S63845
Sensitive
:
C3
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
S63845 + S55746
Sensitive: D – Preclinical
S63845 + S55746
Sensitive
:
D
S63845 + S55746
Sensitive: D – Preclinical
S63845 + S55746
Sensitive
:
D
BCL2L11 deletion
Diffuse Large B Cell Lymphoma
BCL2L11 deletion
Diffuse Large B Cell Lymphoma
S63845
Resistant: D – Preclinical
S63845
Resistant
:
D
S63845
Resistant: D – Preclinical
S63845
Resistant
:
D
BCL2 expression
Diffuse Large B Cell Lymphoma
BCL2 expression
Diffuse Large B Cell Lymphoma
venetoclax + S63845
Sensitive: D – Preclinical
venetoclax + S63845
Sensitive
:
D
venetoclax + S63845
Sensitive: D – Preclinical
venetoclax + S63845
Sensitive
:
D
MCL1 expression
Diffuse Large B Cell Lymphoma
MCL1 expression
Diffuse Large B Cell Lymphoma
venetoclax + S63845
Sensitive: D – Preclinical
venetoclax + S63845
Sensitive
:
D
venetoclax + S63845
Sensitive: D – Preclinical
venetoclax + S63845
Sensitive
:
D
MCL1 expression
Diffuse Large B Cell Lymphoma
MCL1 expression
Diffuse Large B Cell Lymphoma
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
BCL2 expression
Diffuse Large B Cell Lymphoma
BCL2 expression
Diffuse Large B Cell Lymphoma
S63845
Resistant: D – Preclinical
S63845
Resistant
:
D
S63845
Resistant: D – Preclinical
S63845
Resistant
:
D
MCL1 expression
Multiple Myeloma
MCL1 expression
Multiple Myeloma
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
BCL2 expression
Multiple Myeloma
BCL2 expression
Multiple Myeloma
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
ATM deletion + SF3B1 mutation
Chronic Lymphocytic Leukemia
ATM deletion + SF3B1 mutation
Chronic Lymphocytic Leukemia
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
CD34 positive
Acute Myelogenous Leukemia
CD34 positive
Acute Myelogenous Leukemia
S63845 + BMIi-1
Sensitive: D – Preclinical
S63845 + BMIi-1
Sensitive
:
D
S63845 + BMIi-1
Sensitive: D – Preclinical
S63845 + BMIi-1
Sensitive
:
D
CD34 positive + MN1 overexpression + MCL1 elevation
Acute Myelogenous Leukemia
CD34 positive + MN1 overexpression + MCL1 elevation
Acute Myelogenous Leukemia
S63845 + BMIi-1
Sensitive: D – Preclinical
S63845 + BMIi-1
Sensitive
:
D
S63845 + BMIi-1
Sensitive: D – Preclinical
S63845 + BMIi-1
Sensitive
:
D
BRAF V600E
Melanoma
BRAF V600E
Melanoma
encorafenib + S63845
Sensitive: D – Preclinical
encorafenib + S63845
Sensitive
:
D
encorafenib + S63845
Sensitive: D – Preclinical
encorafenib + S63845
Sensitive
:
D
BST1 positive
Acute Myelogenous Leukemia
BST1 positive
Acute Myelogenous Leukemia
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
S63845 + A-1331852
Sensitive: D – Preclinical
S63845 + A-1331852
Sensitive
:
D
S63845 + A-1331852
Sensitive: D – Preclinical
S63845 + A-1331852
Sensitive
:
D
FBXW7 underexpression
Breast Cancer
FBXW7 underexpression
Breast Cancer
JQ-1 + S63845
Sensitive: D – Preclinical
JQ-1 + S63845
Sensitive
:
D
JQ-1 + S63845
Sensitive: D – Preclinical
JQ-1 + S63845
Sensitive
:
D
MCL1 overexpression + HER-2 amplification
Breast Cancer
MCL1 overexpression + HER-2 amplification
Breast Cancer
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
S63845
Sensitive: D – Preclinical
S63845
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login